Your email has been successfully added to our mailing list.

×
0.101321585903084 0.101321585903084 0.101321585903084 0.101321585903084 0.101321585903084 0.101321585903084 0.101321585903084 0.101321585903084
Stock impact report

XBiotech Inc.: Attractive Takeover Target After Compelling Phase II Atopic Dermatitis Results [Seeking Alpha]

XBiotech Inc. (XBIT)  More Company Research Source: Seeking Alpha
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF XBiotech Inc.: Attractive Takeover Target After Compelling Phase II Atopic Dermatitis ResultsSummaryEarly results in Phase II Atopic Dermatitis (AD) trial delivers stellar results.Global market for AD currently around $4B with 7.8% CAGR through 2023.Superior outcomes may challenge the current standard of care. [Read more]
Impact snapshot Event time: XBIT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
XBIT alerts
from News Quantified
Opt-in for
XBIT alerts

from News Quantified
Opt-in for
XBIT alerts

from News Quantified